GlassScriptPhysician profile
Daniel Lauren Dasher
NPI 1689163685
$3,477.68
in general payments reported to CMS, 2019-2025
30 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $515 · 2022: $574 · 2023: $1,033 · 2024: $1,082 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,389.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $427.02 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $422.94 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $266.22 | 2022-2024 | Dupixent |
| Amgen INC. | $241.82 | 2021-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $237.97 | 2022-2025 | Nucala, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.47 | 2021-2024 | Jardiance |
| Dexcom, INC. | $199.62 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $199.11 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Genzyme Corporation | $182.72 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $157.22 | 2021-2024 | Livalo, Seglentis |
| Lilly USA, LLC | $112.62 | 2022-2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $98.34 | 2022-2024 | Quviviq |
| Pfizer INC. | $92.47 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $83.13 | 2021-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $64.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $64.66 | 2024-2025 | Xembify |
| Biohaven Pharmaceutical Holding Company LTD. | $62.03 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.41 | 2021-2025 | Cuvitru |
| Csl Behring | $49.26 | 2023-2024 | Haegarda, Hizentra |
| Sanofi-Aventis U.S. LLC | $46.08 | 2022-2023 | |
| Octapharma USA, INC. | $43.14 | 2024-2025 | Cutaquig |
| Teva Pharmaceuticals USA, INC. | $30.98 | 2021-2023 | Ajovy |
| Sanofi Pasteur INC. | $19.69 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.94 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.13 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $14.79 | 2022 | |
| Kaleo, INC. | $14.47 | 2021 | |
| Baxter Healthcare | $14.16 | 2022 | |
| Ibsa Pharma INC. | $13.90 | 2025 | Flector, Tirosint, Licart |
| Abbott Laboratories | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.